Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.It is used off-label outside its FDA approval for Behçet's disease and other conditions. Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals. It cannot be given by mouth because the digestive system would destroy the drug.

英夫利昔单抗是一种嵌合单克隆抗体生物学药物不利于肿瘤坏死因子-α (tumor necrosis factor-α，TNF-α) 用于治疗自身免疫性疾病.英夫利昔单抗经美国食品和药物管理局 (FDA) 治疗克罗恩病，溃疡性结肠炎，牛皮癣，银屑病关节炎、强直性脊柱炎、类风湿关节炎.它是用于适应症外 FDA 批准白塞病等情况.英夫利昔单抗是通过静脉内输注，通常在六到八周的间隔.它不能口服因为消化系统会摧毁.